Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant EndoTAG-1 plus paclitaxel in HER2-negative high-risk breast cancer
2011-002985-19Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Sep 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EndoTAG-1 and paclitaxel in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Percent reduction in MRI-estimated tumor volume. Started Sep 2011; status: completed.
02
Drugs
EndoTAG-1paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-002985-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002985-19.